Baxter International stock rebounds after months of steady decline

From March lows to rising moving averages, Baxter's turnaround is catching Wall Street's eye. Could this be the start of a lasting rally?

, and Administrator

2026 May 24 . 2:01 PM

1 min read

The image shows a graph depicting the number of businesses in the U.S. who have been affected by... — The image shows a graph depicting the number of businesses in the U.S. who have been affected by the COVID-19 pandemic, with the text indicating that the economy is recovering from the pandemic. The graph is divided into two sections, one for recovery and one for economic recovery, and each section is further divided into subsections, each representing a different industry. The text on the left side of the image provides further information about the data, such as the total number of companies affected and the total economic recovery.

Baxter International stock rebounds after months of steady decline

Baxter International (BAX) has shown signs of recovery after a challenging period. The healthcare company, valued at $9.7 billion, supplies essential medical products globally. Recent market movements suggest growing investor interest in the stock. BAX shares hit a low of around $16 in late March. Since then, the stock has climbed steadily, reflecting improved sentiment. Technical indicators now point to a stronger trend, with both the 20-day and 50-day moving averages turning upward. The Percentage Price Oscillator (PPO) has also shifted sharply higher, reinforcing the positive momentum.

At the company’s 2026 annual meeting, shareholders approved all proposed corporate measures. Analysts currently rate BAX as a 'Hold,' with a forward earnings multiple of 9.6x and a sales multiple of 0.84x. The stock’s 60-month beta of 0.62 signals lower volatility compared to the broader S&P 500 index. BAX’s recent rally and technical improvements suggest a shift in market perception. The company’s stable valuation and lower volatility may appeal to cautious investors. For now, Wall Street remains neutral, awaiting further developments before adjusting its stance.